Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Cardiol Therapeutics Files Preliminary Prospectus Supplement For Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed
Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
Cardiol Therapeutics Inc. (納斯達克:CRDL) (tsx:CRDL) ("Cardiol"或"公司"), 一家臨床階段的生命科學公司,專注於心髒病治療的抗炎和抗纖維化治療的研究和臨床開發,很高興宣佈公司已就擬議中的公開發行(Class A普通股"Common Shares")提交了一份初步招股書補充("Supplement"), 以補充其短表基礎招股說明書,日期爲2024年7月12日("基礎招股說明書")。該補充文件還在美國證券交易委員會(SEC)提交,作爲一項Form-10修正的註冊聲明的一部分,該註冊聲明已於2024年7月16日獲得SEC批准,符合加拿大與美國之間建立的多司法披露系統。
The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis, and for general and administrative expenses, working capital and other expenses.
公司打算利用本次發行的淨收益支持用於治療複發性心包炎的CardiolRx的臨床開發,以及用於一般和管理性費用、營運資金和其他支出。
Canaccord Genuity is acting as the sole bookrunner in connection with the Offering.
Canaccord Genuity將擔任發行的唯一包銷商。
